Evaluation of PDE4 inhibition for COPD.
Targeting type 4 phosphodiesterase (PDE4) for treatment of COPD has multilevel benefits to patients by reducing inflammation, relieving bronchoconstriction, and improving pulmonary circulation. The isoenzyme-specific narrow spectrum PDE4 inhibitors such as cilomilast and roflumilast may have limited clinical efficacy in managing severe and very severe COPD. Development of dual therapy by combining PDE4 inhibition with Ca2+ channel antagonism may introduce an effective novel armory for physicians to manage patients with severe COPD.
Wang
Desuo
D
South Carolina College of Pharmacy, University of South Carolina, 715 Sumter St, Columbia, SC 29208, USA. wang@cop.sc.edu
Cui
Xiangli
X
D000631:Aminopyridines / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D001549:Benzamides / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000494:pharmacology* / Q000627:therapeutic use; D002264:Carboxylic Acids / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D003509:Cyclohexanecarboxylic Acids; D003521:Cyclopropanes / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D009570:Nitriles / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D058988:Phosphodiesterase 4 Inhibitors; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology*; D011652:Pulmonary Circulation / Q000187:drug effects; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy*; D012720:Severity of Illness Index
D000631:Aminopyridines; D001549:Benzamides; D002121:Calcium Channel Blockers; D002264:Carboxylic Acids; D003509:Cyclohexanecarboxylic Acids; D003521:Cyclopropanes; D009570:Nitriles; D058988:Phosphodiesterase 4 Inhibitors; D010726:Phosphodiesterase Inhibitors; C424423:Roflumilast; C433247:Cilomilast